Cancer

Erimos Pharmaceuticals Announces Phase I Continuos Intravenous Infusion Study of Terameprocol (EM-1421)

Published in Law and Health Weekly, June 30th, 2007

Erimos Pharmaceuticals, a growing biopharmaceutical company focused on the discovery and development of new therapeutics to treat cancer and other serious diseases, announced that patient dosing has commenced in a weekly dose Phase I study for its lead product candidate, terameprocol (EM-1421), for the treatment of solid tumors that are unresponsive to conventional therapy.

Terameprocol, a synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA), is exclusively licensed by Erimos from The Johns Hopkins University for use in various diseases. Working at the DNA level, terameprocol is designed to prevent the production and activation of survivin, a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2007-06-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry